{"title":"The Presence of Non-Exhausted Senescent T Cells in Breast Cancer Patients.","authors":"Sikrit Denariyakoon, Athina Giannoudis, Charoenchai Puttipanyalears, Kris Chatamra, Apiwat Mutirangura","doi":"10.31557/APJCP.2025.26.5.1633","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the presence of cancer-associated senescent T cells in breast cancer patients and the impact of the progression of age on their senescent phenotypes.</p><p><strong>Methods: </strong>The exhausted T cell lineage was excluded from the analysis of T cells by using PD1 marker. The percentages of CD28- cells were used to determine the senescent phenotype, in which the CD57 expression was used to further characterize their phenotypes. The flow cytometry was used on CytoFLEX flow cytometer and analysed with CytExpert analysis software.</p><p><strong>Results: </strong>In this study, both senescent and non-exhausted senescent T cells were significantly increased in breast cancer patients. However, non-exhausted T cells could demonstrate more significant proportion of senescent T cells, and these phenotypes in CD8+ T cells were increased in breast cancer patients, which were 53.03% and 37.25% (p<0.001). Moreover, CD28-CD57- cells of non-exhausted CD8+ T cells were increased irrespective of age, while the increase in CD28-CD57+ cells was positively correlated with the progression of age (r=0.353, p=0.015). In addition, the predominant CD28-CD57- cells were attenuated after 52 years of age.</p><p><strong>Conclusion: </strong>The presence of non-exhausted senescent T cells seemed to be a concern regarding immune dysfunction in breast cancer patients. These phenotypes were presented in both young-age and old-age breast cancer, but the terminal phenotype seemed to be abundant in the elderly.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 5","pages":"1633-1640"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290185/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.5.1633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to investigate the presence of cancer-associated senescent T cells in breast cancer patients and the impact of the progression of age on their senescent phenotypes.
Methods: The exhausted T cell lineage was excluded from the analysis of T cells by using PD1 marker. The percentages of CD28- cells were used to determine the senescent phenotype, in which the CD57 expression was used to further characterize their phenotypes. The flow cytometry was used on CytoFLEX flow cytometer and analysed with CytExpert analysis software.
Results: In this study, both senescent and non-exhausted senescent T cells were significantly increased in breast cancer patients. However, non-exhausted T cells could demonstrate more significant proportion of senescent T cells, and these phenotypes in CD8+ T cells were increased in breast cancer patients, which were 53.03% and 37.25% (p<0.001). Moreover, CD28-CD57- cells of non-exhausted CD8+ T cells were increased irrespective of age, while the increase in CD28-CD57+ cells was positively correlated with the progression of age (r=0.353, p=0.015). In addition, the predominant CD28-CD57- cells were attenuated after 52 years of age.
Conclusion: The presence of non-exhausted senescent T cells seemed to be a concern regarding immune dysfunction in breast cancer patients. These phenotypes were presented in both young-age and old-age breast cancer, but the terminal phenotype seemed to be abundant in the elderly.
期刊介绍：
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
